IN THE SPECIFICATION

Please replace the paragraph starting on page 20, line 4, with the following rewritten paragraph.

C1

In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO:1. NHRP-1 is 260 amino acids in length and has a potential ATP/GTP binding motif from G234 to Y241. NHRP-1 has sequence homology with Saccharomyces cerevisiae chromosome 5, GI 603365, and is associated with cDNA libraries which are immortalized or cancerous and show inflammatory or immune responses.

Please replace the paragraph starting on page 20, line 14, with the following rewritten paragraph.

C2

In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO:2. NHRP-2 is 153 amino acids in length and has a potential signature for regulating chromosome condensation from A136 to V146 . NHRP-2 has sequence homology with S. pombe chromosome 1, GI 1322397, and is associated with cDNA libraries which are immortalized or cancerous.

Please replace the paragraph starting on page 20, line 25, with the following rewritten paragraph.

C3

In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO:3. NHRP-3 is 185 amino acids in length and has several potential phosphorylation sites at T30, S44, T53, S104, S126, S150, and S181. NHRP-3 has sequence homology with Caenorhabditis elegans, GI 899244, and is associated with cDNA libraries which are immortalized or cancerous and show inflammatory or immune responses.

Please replace the paragraph starting on page 21, line 6, with the following rewritten paragraph.

C4

In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO:4. NHRP-4 is 106 amino acids in length and has eight potential posttranslational processing sites at Y36, M37, L39, W58, A60, M80, M81, and M85. NHRP-4

C4 Conclude has sequence homology with C. elegans, GI 860698, and is associated with cDNA libraries which are immortalized or cancerous.

Please replace the paragraph starting on page 21, line 17, with the following rewritten paragraph.

C5 In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO:5. NHRP-5 is 166 amino acids in length and has two potential ATP/GTP binding motifs from G69 to S76 and G74 to Q81 and a cyclophilin-type peptidyl-prolyl cis-trans isomerase signature from Y48 to G65. NHRP-5 has sequence homology with C. elegans, GI 1330343, and is associated with cDNA libraries which are immortalized or cancerous and show inflammatory or immune responses.

Please replace the paragraph starting at page 21, line 28 and ending at page 22, line 2, with the following rewritten paragraph.

C6 In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO:6. NHRP-6 is 173 amino acids in length and has a potential ATP/GTP binding motif from G118 to S125. NHRP-6 has sequence homology with C. elegans, GI 1330401, and is associated with cDNA libraries which are immortalized or cancerous and show inflammatory or immune responses.

Please replace the paragraph starting on page 22, line 8, with the following rewritten paragraph.

C7 In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO:7. NHRP-7 is 245 amino acids in length and has a potential ATP/GTP binding site motif from G158 to T165 and a potential signature for regulating chromosome condensation from M62 to V72. NHRP-7 has sequence homology with S. cerevisiae, GI 1314090 , and is associated with cDNA libraries which are immortalized or cancerous and show inflammatory or immune responses.

Please replace the paragraph starting on page 22, line 19, with the following rewritten paragraph.

C8

In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO:8. NHRP-8 is 198 amino acids in length and has a potential EGF cysteine pattern signature from C60 to M71 and an N-6 adenine -specific DNA methylase signature from V123 to F129. NHRP-8 has sequence homology with C. elegans, GI 559422 , and is associated with cDNA libraries which are immortalized or cancerous and show inflammatory or immune responses.

Please replace the paragraph starting at page 22, line 30 and ending at page 23, line 5, with the following rewritten paragraph.

C9

In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO:9. NHRP-9 is 224 amino acids in length and has a potential ATP/GTP binding motif from G11 to G18, and a Bzip transcription factor signature from K56 to R71. NHRP-9 has sequence homology with C. elegans, GI 868241, and is associated with cDNA libraries which are immortalized or cancerous and show inflammatory or immune responses.

Please replace the paragraph starting on page 23, line 12, with the following rewritten paragraph.

C10

In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO:10. NHRP-10 is 180 amino acids in length and has a potential signature for regulating chromosome condensation from S104 to L118. NHRP-10 has sequence homology with S. cerevisiae, GI 486601, and is associated with cDNA libraries which are immortalized or cancerous and show inflammatory or immune responses.

Please replace the paragraph starting on page 23, line 22, with the following rewritten paragraph.

C11

In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO:11. NHRP-11 is 98 amino acids in length and has a potential copper binding region signature from Q43 to F47, a potential immunoglobulin-Mhc signature from F40

C11 Conclude

to H46, and a potential thiol protease motif from H45 to V56, all essentially in the same region of the molecule. NHRP-11 has sequence homology with S. pombe, GI 1008989, and is associated with cDNA libraries which are immortalized or cancerous and show inflammatory or immune responses.

Please replace the paragraph starting on page 24, line 4, with the following rewritten paragraph.

C12

In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO:12. NHRP-12 is 168 amino acids in length and has cytochrome c-like motif from K84 to K89. NHRP-12 has sequence homology with C. elegans, GI 687880, and is associated with cDNA libraries which are immortalized or cancerous and show inflammatory or immune responses.

Please replace the paragraph starting on page 24, line 14, with the following rewritten paragraph.

C13

In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO:13. NHRP-13 is 247 amino acids in length and has a potential ATP/GTP binding motif from A71 to A78; a potential Myb DNA-binding domain from K183 to L191; and a zinc finger binding motif from C135 to H158. NHRP-13 has sequence homology with C. elegans, GI 1627533, and is associated with cDNA libraries which are immortalized or cancerous and show inflammatory or immune responses.

Please replace the paragraph starting on page 24, line 25, with the following rewritten paragraph.

C14

In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO:14. NHRP-14 is 259 amino acids in length and has a potential signature for regulating chromosome condensation from A26 to V36. NHRP-14 has sequence homology with C. elegans, GI 527429, and is associated with cDNA libraries which are immortalized or cancerous and show inflammatory or immune responses.

Please replace the paragraph starting on page 25, line 5, with the following rewritten paragraph.

C15 In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO:15. NHRP-15 is 165 amino acids in length and has two potential phosphorylation sites at S13 and S104. NHRP-15 has sequence homology with C. elegans, GI 687847, and is associated with cDNA libraries which are immortalized or cancerous.

Please replace the paragraph starting on page 25, line 15, with the following rewritten paragraph.

C16 In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO:16. NHRP-16 is 89 amino acids in length and has a potential growth factor receptor signature from C53 to W66. NHRP-16 has sequence homology with Arabidopsis thaliana, GI 1707018, and is associated with cDNA libraries which are immortalized or cancerous and show inflammatory or immune responses.

Please replace the paragraph starting on page 25, line 25, with the following rewritten paragraph.

C17 In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO:17. NHRP-17 is 82 amino acids in length and has a potential glycosylation site at N31 and a potential phosphorylation site at T35. NHRP-17 has sequence homology with C. elegans, GI 1122819, and is associated with cDNA libraries which are immortalized or cancerous and show inflammatory or immune responses.

Please replace the paragraph starting on page 26, line 5, with the following rewritten paragraph.

C18 In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO:18. NHRP-18 is 259 amino acids in length and has a potential cytokine receptor signature from C122 to W134; an H4 DNA binding signature from G28 to Y32; and a G-beta repeat from L232 to F246. NHRP-18 has sequence homology with C. elegans, GI 662895, and is associated with cDNA libraries which are immortalized or cancerous and show inflammatory or immune responses.

Please replace the paragraph starting on page 26, line 16, with the following rewritten paragraph.

C19

In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO:19. NHRP-19 is 131 amino acids in length and has a potential ATP/GTP binding motif from A100 to T107 and a potential protein splicing signature from V102 to T107. NHRP-19 has sequence homology with C. elegans, GI 733555, and is associated with cDNA libraries which are immortalized or cancerous and show inflammatory or immune responses.

Please replace the paragraph starting at page 26, line 27 and ending at page 27, line 1, with the following rewritten paragraph.

C20

In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO:20. NHRP-20 is 167 amino acids in length and has potential ATP/GTP binding motifs from G62 to C69 and V99 to T106. NHRP-20 has sequence homology with C. elegans, GI 6656, and is associated with cDNA libraries which are immortalized or cancerous and show inflammatory or immune responses.

Please replace the paragraph starting on page 27, line 6, with the following rewritten paragraph.

C21

In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO:21. NHRP-21 is 96 amino acids in length and has a potential protein splicing signature from I20 to T25. NHRP-21 has sequence homology with C. elegans, GI 995857 and is associated with cDNA libraries of fetal origin.

Please replace the paragraph starting on page 27, line 15, with the following rewritten paragraph.

C22

In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO:22. NHRP-22 is 133 amino acids in length and has a potential ATP/GTP binding motif from A116 to S123. NHRP-22 has sequence homology with C. elegans, GI 1177284, and is associated with cDNA libraries which are immortalized or cancerous and show inflammatory or immune responses.

Please replace the paragraph starting on page 27, line 25, with the following rewritten paragraph.

C23

In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO:23. NHRP-23 is 109 amino acids in length and has several potential phosphorylation sites at S68, T93, T101, and S102. NHRP-23 has sequence homology with C. elegans, GI 1469002, and is associated with cDNA libraries which are immortalized or cancerous and show inflammatory or immune responses.

Please replace the paragraph starting on page 28, line 6, with the following rewritten paragraph.

C24

In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO:24. NHRP-24 is 138 amino acids in length and has five potential posttranslational processing sites at G16 to M26 and L35, A36, G38, and F42. NHRP-24 has sequence homology with C. elegans, GI 746540, and is associated with cDNA libraries which are immortalized or cancerous and show inflammatory or immune responses.

Please replace the paragraph starting on page 28, line 16, with the following rewritten paragraph.

C25

In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO:25. NHRP-25 is 100 amino acids in length and has potential zinc finger motifs from C25 to H47 and C45 to H66. NHRP-25 has sequence homology with a human tRNA pseudogene, GI 292845, and is associated with cDNA libraries which are immortalized or cancerous and show inflammatory or immune responses.

Please replace the paragraph starting at page 28, line 28 and ending on page 29, line 3, with the following rewritten paragraph.

C26

In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO:26. NHRP-26 is 314 amino acids in length and has a potential ATP/GTP binding site from A65 to Q72 and a potential Myb DNA-binding domain from W55 to V63. NHRP-26 has sequence homology with S. cerevisiae, GI 1302480, and is associated with

C24 Conclude cDNA libraries which are immortalized or cancerous and show inflammatory or immune responses.

Please replace the paragraph starting on page 29, line 9, with the following rewritten paragraph.

C27 In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO:27. NHRP-27 is 140 amino acids in length and has a potential ATP/GTP binding site from A68 to T75. NHRP-27 has sequence homology with S. cerevisiae, GI 603277, and is associated with cDNA libraries which are immortalized or cancerous and show inflammatory or immune responses.

Please replace the paragraph starting on page 29, line 19, with the following rewritten paragraph.

C28 In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO:28. NHRP-28 is 125 amino acids in length and has a potential ATP/GTP binding site from A60 to T67. NHRP-28 has sequence homology with C. elegans, GI 1523895, and is associated with cDNA libraries which are immortalized or cancerous and show inflammatory or immune responses.

Please replace the paragraph starting at page 29, line 29 and ending at page 30, line 4, with the following rewritten paragraph.

C29 In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO:29. NHRP-29 is 142 amino acids in length and has a potential FKBP-type peptidylprolyl cis-trans isomerase signature from M1 to A17. NHRP-29 has sequence homology with S. cerevisiae, GI 1230688, and is associated with cDNA libraries which are immortalized or cancerous and show inflammatory or immune responses.

Please replace the paragraph starting on page 30, line 11, with the following rewritten paragraph.

C30 In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO:30. NHRP-30 is 310 amino acids in length and has a potential

ATP/GTP binding site from A271 to Q278. NHRP-30 has sequence homology with S. cerevisiae, GI 836759, and is associated with cDNA libraries which are immortalized or cancerous and show inflammatory or immune responses.

Please replace the paragraph starting on page 30, line 21, with the following rewritten paragraph.

In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO:31. NHRP-31 is 209 amino acids in length and has a potential receptor protein signature from M1 to E18. NHRP-31 has sequence homology with S. cerevisiae, GI 1431368, and is associated with cDNA libraries which are immortalized or cancerous and show inflammatory or immune responses.

Please replace the paragraph starting on page 31, line 1, with the following rewritten paragraph.

In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO:32. NHRP-32 is 110 amino acids in length and has four cysteine rich cytochrome c-like signatures from C23 to G28, C30 to S35, C58 to G63, and C72 to I77. NHRP-32 has sequence homology with S. cerevisiae, GI 1230697, and is associated with cDNA libraries which are immortalized or cancerous and show inflammatory or immune responses.

Please replace the paragraph starting on page 31, line 13, with the following rewritten paragraph.

In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO:33. NHRP-33 is 264 amino acids in length and has two potential lipocalin signatures at N149 and G151. NHRP-33 has sequence homology with C. elegans, GI 1523932, and is associated with cDNA libraries which are immortalized or cancerous and show inflammatory or immune responses.

Please replace the paragraph starting on page 31, line 23, with the following rewritten paragraph.

C34 In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO:34. NHRP-34 is 153 amino acids in length and has a potential ATP/GTP binding motif from E143 to N152. NHRP-34 has sequence homology with C. elegans, GI 1067081, and is associated with cDNA libraries which are immortalized or cancerous and show inflammatory or immune responses.

Please replace the paragraph starting on page 32, line 3, with the following rewritten paragraph.

C35 In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO:35. NHRP-35 is 150 amino acids in length. NHRP-35 has sequence homology with C. elegans, GI 1703579, and is associated with cDNA libraries which are immortalized or cancerous and show inflammatory or immune responses.

Please replace the paragraph starting on page 32, line 13, with the following rewritten paragraph.

C36 In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO:36. NHRP-36 is 139 amino acids in length and has a potential C-type lectin domain from C14 to C40. NHRP-36 has sequence homology with S. cerevisiae, GI 1322550, and is associated with cDNA libraries which are immortalized or cancerous and show inflammatory or immune responses.

Please replace the paragraph starting on page 32, line 24, with the following rewritten paragraph.

C37 In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO:37. NHRP-37 is 350 amino acids in length and has two potential glycosylation sites at N147 and N185, and several potential phosphorylation sites at S9, S17, T80, T122, S171, T174, T187, T237, S293, S313, T315, S329, S340, and T342. NHRP-37 has sequence homology with S. cerevisiae, GI 1322869, and is associated with cDNA libraries which are immortalized or cancerous and show inflammatory or immune responses.